UBS: Novo Nordisk Wegovy shows strong NBRx momentum; Hims & Hers to buy Eucalyptus

Wegovy pill shows strong new‑prescription momentum, UBS says

UBS analysts led by Matthew Weston report that U.S. new‑to‑brand prescription (NBRx) trends for obesity GLP‑1s show a robust start for Novo Nordisk’s Wegovy pill, with data through Feb. 6, 2026 indicating both starter‑dose and total‑dose momentum. The team highlights an early uptick in Wegovy pen NBRx at the start of the year alongside the pill launch, and notes a high proportion of pill NBRx relative to total prescriptions (TRx), which suggests limited cannibalisation of pen volumes to date.

Regulatory and payer developments are adding to demand signals. The European Commission clears a higher 7.2 mg maintenance dose of Wegovy, expanding prescribers’ dosing options in Europe and reinforcing semaglutide demand. UBS flags Medicare coverage that begins in July and an imminent high‑dose Wegovy 7.2 mg launch as key catalysts for adoption and prescribing patterns later in the year, while noting that competitive entrants such as Eli Lilly’s orforglipron represent a material later‑year dynamic.

UBS underscores that durable market share and revenue depend on both starter‑dose NBRx momentum and sustained TRx, calling for close tracking of real‑world adoption by geography and specialty, refill behaviour, labeling updates and payer actions. The analysts emphasise that refill rates, specialty mix and local payer restrictions will be crucial to model pricing dynamics and penetration through 2026, and that observed early pill uptake combined with dose expansion could materially reshape treatment patterns if maintained.

Strategic digital health acquisition widens Hims & Hers footprint

Separately, Hims & Hers announces a definitive agreement to acquire digital health company Eucalyptus, a move the telehealth firm describes as strategically transformative to accelerate its international expansion, broaden clinical capabilities and integrate virtual care technology with its consumer health platform.

Deal execution and integration milestones attract investor and industry attention, with management citing operational synergies, expanded clinician networks and potential cross‑border product distribution as key objectives. Stakeholders are watching regulatory clearances, cultural integration and retention of clinical talent as determinants of the transaction’s success.